

This article was downloaded by: [Michigan State University]

On: 29 December 2014, At: 00:41

Publisher: Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Journal of Carbohydrate Chemistry

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/lcar20>

Synthetic Studies on Sialoglycoconjugates 85: Synthesis of Sialyl Lewis X Ganglioside Analogs Containing a Variety of Anionic Substituents in Place of Sialic Acid

Masahiro Yoshida ^a, Yukiko Kawakami ^a, Hideharu Ishida ^a, Makoto Kiso ^a & Akira Hasegawa ^a

^a Department of Applied Bioorganic Chemistry, Gifu University, Gifu, 501-11, Japan

Published online: 22 Aug 2006.

To cite this article: Masahiro Yoshida, Yukiko Kawakami, Hideharu Ishida, Makoto Kiso & Akira Hasegawa (1996) Synthetic Studies on Sialoglycoconjugates 85: Synthesis of Sialyl Lewis X Ganglioside Analogs Containing a Variety of Anionic Substituents in Place of Sialic Acid, Journal of Carbohydrate Chemistry, 15:4, 399-418, DOI: [10.1080/07328309608005662](https://doi.org/10.1080/07328309608005662)

To link to this article: <http://dx.doi.org/10.1080/07328309608005662>

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms &

**SYNTHETIC STUDIES ON SIALOGLYCOCONJUGATES 85:
SYNTHESIS OF SIALYL LEWIS X GANGLIOSIDE
ANALOGS CONTAINING A VARIETY OF ANIONIC
SUBSTITUENTS IN PLACE OF SIALIC ACID**

Masahiro Yoshida, Yukiko Kawakami, Hideharu Ishida, Makoto Kiso,
and Akira Hasegawa*

Department of Applied Bioorganic Chemistry, Gifu University,
Gifu 501-11, Japan

Received October 14, 1995 - Final Form January 23, 1996

ABSTRACT

Three sialyl-Le^x ganglioside analogs containing carboxymethyl, sulfate, and phosphate groups in place of the sialic acid moiety, have been synthesized. Glycosylation of 2-(trimethylsilyl)ethyl *O*-(2,3,4-tri-*O*-benzyl- α -L-fucopyranosyl)-(1 \rightarrow 3)-*O*-(2-acetamido-6-*O*-benzyl-2-deoxy- β -D-glucopyranosyl)-(1 \rightarrow 3)-2,4,6-tri-*O*-benzyl- β -D-galactopyranoside (**10**) with methyl 2,4,6-tri-*O*-benzoyl-3-*O*-(methoxycarbonyl)methyl-1-thio- β -D-galactopyranoside (**6**) or methyl 2-*O*-benzoyl-4,6-*O*-benzylidene-3-*O*-levulinoyl-1-thio- β -D-galactopyranoside (**9**) using dimethyl-(methylthio)sulfonium triflate (DMTST) as a promoter, afforded the corresponding tetrasaccharide derivatives **11** and **19**. Compounds **11** and **19** were converted into the α -trichloroacetimidates **14** and **23**, via reductive removal of the benzyl and benzylidene groups, *O*-acetylation, removal of the 2-(trimethylsilyl)ethyl group, and treatment with trichloroacetonitrile, which, on coupling with (2*S*, 3*R*, 4*E*)-2-azido-3-*O*-benzoyl-4-octadecene-1,3-diol (**15**) or 2-(tetradecyl)hexadecan-1-ol (**24**), gave the lipophilic derivatives **16** and **25**. Compound **16** was transformed, via selective reduction of the azido group, condensation with octadecanoic acid, *O*-deacylation, and hydrolysis of the methyl ester group, into the title compound **18** in good yield. Compound **25** was treated with hydrazine acetate to give compound **26**, which in turn was transformed, via sulfation or phosphorylation, and *O*-deacylation, into the target compounds **28** and **31**.

INTRODUCTION

Sialyl-Le^x was first isolated¹ from human kidney and found² to be widespread as the tumor-associated antigen. Recently, it has been demonstrated that the selectins³⁻⁶, such as E-, P-, and L-selectin, recognize the sialyl-Le^x determinant, α -Neu5Ac-(2→3)- β -D-Gal-(1→4)-[α -L-Fuc-(1→3)]- β -D-GlcNAc, which is found as the terminal carbohydrate structure of both cell membrane glycolipids and glycoproteins.

Previously, we reported⁷ the synthesis of sulfo-Le^x analogs containing a ceramide or 2-(tetradecyl)hexadecyl residue, and examined⁸ their competitive inhibition as well as binding activity to selectin-mediated adhesion. Interestingly, these sulfo-Le^x analogs, inhibited strongly the binding between the selectins and the sialyl-Le^x ganglioside, indicating an important influence for this reaction. In view of these facts, we describe herein the synthesis of sialyl-Le^x ganglioside analogs containing a variety of anionic substituents in place of sialic acid in sialyl-Le^x ganglioside, to clarify the effect of anionic groups for the selectin recognition.

RESULTS AND DISCUSSION




For the synthesis of carboxymethyl-, sulfo-, and phosphono-Le^x lipophilic derivatives, we selected 2-(trimethylsilyl)ethyl *O*-(2,3,4-tri-*O*-benzyl- α -L-fucopyranosyl)-(1→3)-*O*-(2-acetamido-6-*O*-benzyl-2-deoxy- β -D-glucopyranosyl)-(1→3)-2,4,6-tri-*O*-benzyl- β -D-galactopyranoside⁹ (**10**) as the glycosyl acceptor, and methyl 2,4,6-tri-*O*-benzoyl-3-*O*-(methoxycarbonyl)methyl-1-thio- β -D-galactopyranoside (**6**) and methyl 2-*O*-benzoyl-4,6-*O*-benzylidene-3-*O*-levulinoyl-1-thio- β -D-galactopyranoside (**9**) as the key glycosyl donors.


2-(Trimethylsilyl)ethyl 2,4,6-tri-*O*-benzoyl-3-*O*-(methoxycarbonyl)methyl- β -D-galactopyranoside (**3**) was obtained in good yield from 2-(trimethylsilyl)ethyl β -D-galactopyranoside¹⁰ (**1**) *via* dibutyltin oxide-mediated selective 3-*O*-(methoxycarbonyl)methylation using methyl bromoacetate and tetrabutylammonium bromide and subsequent *O*-benzoylation. Treatment¹⁰ of **3** with trifluoroacetic acid in

dichloromethane at room temperature gave the 1-hydroxy compound **4**. When treated with trichloroacetonitrile in dichloromethane in the presence of 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) for 1 h at 0 °C, **4** gave the α -trichloroacetimidate **5** in quantitative yield. The glycosyl donor **6** was prepared from **5** with methylthiotrimethylsilane in the presence of boron trifluoride etherate, in 85% yield.



Selective 3-*O*-levulinoylation of methyl 4,6-*O*-benzylidene-1-thio- β -D-galactopyranoside¹¹ (**7**) with levulinic anhydride in pyridine-dichloromethane at -50 °C, and subsequent *O*-benzoylation afforded the another glycosyl donor **9** in good yield.

The glycosylation of **10** with **6** in dichloromethane using dimethyl(methylthio)sulfonium triflate^{12,13} (DMTST) as the glycosyl promoter, gave the desired Le^x tetrasaccharide derivative **11** in 89% yield. Significant signals in the ¹H NMR spectrum of the **11** were a three-proton singlet at δ 3.56 (*O*-methyl) and a one-proton doublet of doublets at δ 5.44 ($J_{1,2} = 8.6$ Hz, $J_{2,3} = 9.5$ Hz, H-2c), indicating the newly formed glycosidic linkage to be β . In essentially the same way, reaction of **10** with **9** afforded the expected Le^x tetrasaccharide **19** in 46% yield. H-2 proton of the galactose residue at the non-reducing end in the ¹H NMR spectrum of **19** appeared at δ 5.59 ($J_{1,2} = 8.4$ Hz), indicating the structure assigned. Catalytic hydrogenolysis in methanol-acetic acid at 45 °C of the benzyl groups of **11**, or in ethanol-acetic acid at 40 °C of the benzyl and benzylidene groups of **19**, and subsequent *O*-acetylation gave the per-*O*-acyl compounds **12** and **21**, which, on treatment with trifluoroacetic acid in dichloromethane for 1 h at room temperature gave the 1-hydroxy compounds **13** and **22** in 93% and 89% yields, respectively. When treated with trichloroacetonitrile in dichloromethane in the presence of DBU for 1 h at 0 °C, **13** and **22** gave the corresponding α -trichloroacetimidates **14** and **23** in quantitative yields, respectively. The ¹H NMR data for the reducing end Gal unit in **14** [δ 6.50 ($J_{1,2} = 3.7$ Hz, H-1) and 8.64 (C=NH)] and **23** [δ 6.48 ($J_{1,2} = 3.9$ Hz, H-1) and 8.63 (C=NH)] indicated the imidates to be α .





	R ¹	R ²	R ³	R ⁴
19	OSE	H	Bn	benzylidene
20	OSE	H	Ac	benzylidene
21	OSE	H	Ac	Ac
22		H, OH	Ac	Ac
23	H	OC(=NH)CCl ₃	Ac	Ac




	R ¹	R ²	R ³
25	Ac	Bz	Lev
26	Ac	Bz	H
27	Ac	Bz	SO ₃ •pyr.
28	H	H	SO ₃ Na
29	Ac	Bz	XEP
30	Ac	Bz	XEPO
31	H	H	P(O)(ONa) ₂

XEP =



XEPO =



The condensation^{14,15} of (2*S*, 3*R*, 4*E*)-2-azido-3-*O*-benzoyl-4-octadecene-1,3-diol^{16,17} (**15**) with **14** in dichloromethane in the presence of boron trifluoride etherate for 2 h at 0 °C afforded the expected β -glycoside **16** in 38% yield. Selective reduction^{18,19} of the azido group in **16** with hydrogen sulfide in aqueous pyridine for 50 h at 0 °C gave the syrupy amine, which, on coupling with octadecanoic acid using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (WSC) in dichloromethane, gave the ceramide derivative **17** in 61% yield.

O-Deacylation of **17** with sodium methoxide in methanol, and subsequent saponification of the methyl ester group, yielded the target carboxymethyl-Le^x **18** in good yield after chromatography on a column of Sephadex LH-20. The ¹H NMR data of the product thus obtained are consistent with the structure assigned.

The glycosylation^{14,15} of 2-(tetradecyl)hexadecan-1-ol²⁰ (**24**) with **23** in dichloromethane in the presence of boron trifluoride etherate for 21 h at 7 °C afforded the desired lipophilic derivative **25** in 37% yield. Selective removal of the levulinoyl group of **25** performed with hydrazine acetate in ethanol gave the monohydroxy derivative **26** in 87% yield.

Treatment of **26** with sulfur trioxide-pyridine complex in *N,N*-dimethylformamide (DMF) for 4 h at room temperature gave the sulfo derivative as its pyridine salt **27**, and this was transformed, by *O*-deacylation with sodium methoxide in methanol and tetrahydrofuran, into the title sulfo-Le^x sodium salt **28** in good yield.

Treatment of **26** with *o*-xylylene *N,N*-diethylphosphoramidite^{21,22} (XEPA) in dichloromethane in the presence of 1*H*-tetrazole for 13 h at room temperature gave **29**, and this was transformed, *via* oxidation of phosphorus atom with 3-chloroperoxybenzoic acid in dichloromethane, followed by catalytic hydrogenolysis (10% Pd-C) in methanol of the *o*-xylylene group, and *O*-deacylation with sodium methoxide in methanol and tetrahydrofuran, into the target phosphono-Le^x **31** as its sodium salt in high yield.

The synthesized carboxymethyl- (**18**), sulfo- (**28**), and phosphono-Le^x (**31**) ganglioside analogs showed significant competitive inhibition activity between the selectins (E-, P-, and L-selectin) and sialyl-Le^x ganglioside. These results suggest that

the sialic acid part may be replaced by other anionic substituents. The detailed biological results will be published in *J. Med. Chem.*⁸

EXPERIMENTAL

General Procedures. Specific rotations were determined with a Union PM-201 polarimeter at 25 °C and IR spectra were recorded with a Jasco A-100 spectrophotometer. ¹H NMR spectra were recorded with a JEOL JNM-GX 270 spectrometer. Electrospray mass spectra were recorded on an API-III triple quadrupole mass spectrometer (Perkin-Elmer Sciex Instruments, Thornhill, Canada) fitted with an atmospheric pressure ionization source. Preparative chromatography was performed on silica gel (Fuji Silysia Co., 127 mesh) with the solvent systems specified. Concentrations were conducted *in vacuo*.

2-(Trimethylsilyl)ethyl 3-O-(Methoxycarbonyl)methyl-β-D-galactopyranoside (2). A suspension of 2-(trimethylsilyl)ethyl β-D-galactopyranoside¹⁰ (**1**; 1.0 g, 3.6 mmol) and dibutyltin oxide (1.3 g) in MeOH (10 mL) was heated, with stirring, for 6 h at 70 °C then concentrated. To a solution of the residue in benzene (10 mL) were added methyl bromoacetate (1 mL) and tetrabutylammonium bromide (0.6 g), and the mixture was stirred under reflux for 15 min then concentrated. Column chromatography (3:2 AcOEt-hexane) of the residue on silica gel (80 g) gave **2** (870 mg, 69%) as an amorphous mass: $[\alpha]_D -31.0^\circ$ (*c* 1.2, CHCl₃); ¹H NMR (CDCl₃) δ 1.01 (m, 2H, Me₃SiCH₂CH₂), 3.32 (dd, 1H, J_{2,3} = 9.5 Hz, J_{3,4} = 3.4 Hz, H-3), 3.50 (m, 1H, H-5), 3.57, 3.98 (m, 2H, Me₃SiCH₂CH₂), 3.75 (s, 3H, MeO), 4.25 (d, 1H, J_{1,2} = 7.9 Hz, H-1), and 4.28 (m, 2H, MeOCOCH₂).

Anal. Calcd for C₁₄H₂₈O₈Si (352.5): C, 47.71; H, 8.01. Found: C, 47.56; H, 7.78.

2-(Trimethylsilyl)ethyl 2,4,6-Tri-O-benzoyl-3-O-(methoxycarbonyl)methyl-β-D-galactopyranoside (3). To a solution of **2** (910 mg, 2.6 mmol) in pyridine (13 mL) was added benzoyl chloride (1.3 mL, 11.2 mmol), and the mixture was stirred for 2 h at room temperature. After completion of the reaction,

MeOH (3 mL) was added, and the mixture was stirred for 30 min at room temperature, concentrated, and extracted with CH₂Cl₂. The extract was successively washed with 2M HCl and water, dried (Na₂SO₄) and concentrated. Column chromatography (1:3 AcOEt-hexane) of the residue on silica gel (80 g) gave **3** (1.4 g, 82%) as an amorphous mass: $[\alpha]_D +38.4^\circ$ (*c* 1.0, CHCl₃); ¹H NMR (CDCl₃) δ 0.94 (m, 2H, Me₃SiCH₂CH₂), 3.48 (s, 3H, MeO), 3.62 (m, 1H, Me₃SiCH₂CH), 4.18 (d, 2H, J_{gem} = 7.1 Hz, MeOCOCH₂), 4.43 (dd, 1H, J_{gem} = 11.4 Hz, J_{5,6} = 6.1 Hz, H-6), 4.63 (dd, 1H, J_{5,6'} = 7.0 Hz, H-6'), 4.73 (d, 1H, J_{1,2} = 8.1 Hz, H-1), 5.54 (dd, 1H, J_{2,3} = 9.9 Hz, H-2), 5.92 (d, 1H, J_{3,4} = 2.8 Hz, H-4), and 7.26-8.17 (m, 15H, 3Ph).

Anal. Calcd for C₃₅H₄₀O₁₁Si (664.8): C, 63.24; H, 6.07. Found: C, 63.15; H, 5.93.

2,4,6-Tri-*O*-benzoyl-3-*O*-(methoxycarbonyl)methyl-D-galactopyranose (4). To a solution of **3** (2.3 g, 3.5 mmol) in CH₂Cl₂ (15 mL) was added trifluoroacetic acid (10 mL), and the mixture was stirred for 1 h at room temperature and concentrated. Column chromatography (1:2 AcOEt-hexane) of the residue on silica gel (100 g) gave **4** (1.9 g, 95%) as an amorphous mass: IR (film) 3300 (OH), 1750 and 1250 (ester), and 700 cm⁻¹ (Ph).

Anal. Calcd for C₃₀H₂₈O₁₁ (564.5): C, 63.83; H, 5.00. Found: C, 63.66; H, 4.97.

2,4,6-Tri-*O*-benzoyl-3-*O*-(methoxycarbonyl)methyl- α -D-galactopyranosyl trichloroacetimidate (5). To a solution of **4** (820 mg, 1.5 mmol) in CH₂Cl₂ (10 mL) and trichloroacetonitrile (4.4 mL) was added 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU; 0.22 mL) at 0 °C, and the mixture was stirred for 1 h at 0 °C, then concentrated. Column chromatography (2:5 AcOEt-hexane) of the residue on silica gel (100 g) gave **5** (1.0 g, quantitative) as an amorphous mass: $[\alpha]_D +123.2^\circ$ (*c* 1.1, CHCl₃); ¹H NMR (CDCl₃) δ 3.59 (s, 3H, MeO), 4.29 (m, 2H, MeOCOCH₂), 4.45 (m, 2H, H-3 and H-6), 4.55 (dd, 1H, J_{gem} = 11.4 Hz, J_{5,6'} = 6.5 Hz, H-6'), 4.69 (m, 1H, H-5), 5.74 (dd, 1H, J_{1,2} = 3.8 Hz, J_{2,3} = 10.4 Hz, H-

2), 6.12 (d, 1H, $J_{3,4} = 2.6$ Hz, H-4), 6.84 (d, 1H, H-1), 7.26-8.15 (m, 15H, 3Ph), and 8.59 (s, 1H, C=NH).

Anal. Calcd for $C_{32}H_{28}NO_{11}Cl_3$ (708.9): C, 54.22; H, 3.98; N, 1.98. Found: C, 54.05; H, 3.77; N, 1.69.

Methyl 2,4,6-Tri-*O*-benzoyl-3-*O*-(methoxycarbonyl)methyl-1-thio- β -D-galactopyranoside (6). To a solution of **5** (786 mg, 1.1 mmol) in $ClCH_2CH_2Cl$ (11 mL) were added, with stirring, methylthiotrimethylsilane (0.63 mL, 4.5 mmol) and boron trifluoride etherate (0.55 mL), and the mixture was stirred for 3 h at room temperature. CH_2Cl_2 (100 mL) was added, and the solution was washed with M Na_2CO_3 and water, dried (Na_2SO_4) and concentrated. Column chromatography (1:4 AcOEt-hexane) of the residue on silica gel (80 g) gave **6** (561 mg, 85%) as an amorphous mass: $[\alpha]_D +68.7^\circ$ (c 0.9, $CHCl_3$); 1H NMR ($CDCl_3$) δ 2.31 (s, 3H, MeS), 3.48 (s, 3H, MeO), 4.13 (dd, 1H, $J_{2,3} = 9.6$ Hz, $J_{3,4} = 3.2$ Hz, H-3), 4.21 (d, 1H, $J_{gem} = 7.3$ Hz, $MeOCOCH_2$), 4.42 (dd, 1H, $J_{gem} = 11.4$ Hz, $J_{5,6} = 6.0$ Hz, H-6), 4.62 (dd, 1H, $J_{5,6'} = 6.8$ Hz, H-6'), 4.67 (d, 1H, $J_{1,2} = 9.9$ Hz, H-1), 5.67 (t, 1H, H-2), 6.01 (d, 1H, H-4), and 7.26-8.13 (m, 15H, 3Ph).

Anal. Calcd for $C_{31}H_{30}O_{10}S$ (594.6): C, 62.62; H, 5.09. Found: C, 62.32; H, 4.94.

Methyl 4,6-*O*-Benzylidene-3-*O*-levulinoyl-1-thio- β -D-galactopyranoside (8). To a solution of methyl 4,6-*O*-benzylidene-1-thio- β -D-galactopyranoside¹¹ (**7**; 100 mg, 0.34 mmol) in pyridine (3 mL) and CH_2Cl_2 (3 mL), cooled to $-50^\circ C$, were added, with stirring, a solution of levulinic anhydride (179 mg, 0.84 mmol) in CH_2Cl_2 (1 mL) and 4-dimethylaminopyridine (41 mg), and the stirring was continued for 30 min at $-50^\circ C$. MeOH (3 mL) was added to the mixture, concentrated and extracted with CH_2Cl_2 . The extract was successively washed with 2M HCl and water, dried (Na_2SO_4) and concentrated. Column chromatography (1:1 AcOEt-hexane) of the residue on silica gel (50 g) gave **8** (85 mg, 64%) as an amorphous mass: $[\alpha]_D +40.1^\circ$ (c 1.7, CH_2Cl_2); 1H NMR ($CDCl_3$) δ 2.10 (s, 3H, $MeCOCH_2CH_2$), 2.26 (s, 3H, MeS), 2.52-2.88 (m, 4H, $MeCOCH_2CH_2$), 3.58 (s, 1H, H-5), 4.01 (dd, 1H, $J_{gem} = 12.6$ Hz, $J_{5,6} = 1.3$ Hz, H-6), 4.09 (dd, 1H, $J_{1,2} =$

9.3 Hz, $J_{2,3} = 9.7$ Hz, H-2), 4.33 (d, 1H, H-6'), 4.35 (d, 1H, $J_{3,4} = 3.5$ Hz, H-4), 4.36 (d, 1H, H-1), 4.94 (dd, 1H, H-3), and 7.34-7.51 (m, 5H, Ph).

Anal. Calcd for $C_{19}H_{24}O_7S$ (396.5): C, 57.56; H, 6.10. Found: C, 57.32; H, 6.02.

Methyl 2-*O*-Benzoyl-4,6-*O*-benzylidene-3-*O*-levulinoyl-1-thio- β -D-galactopyranoside (9). To a solution of **8** (104 mg, 0.26 mmol) in pyridine (1 mL) was added benzoyl chloride (80 μ L, 0.69 mmol), and the mixture was stirred for 3 h at room temperature. MeOH (0.5 mL) was added to the mixture, concentrated and extracted with CH_2Cl_2 . The extract was successively washed with 2M HCl and water, dried (Na_2SO_4) and concentrated. Column chromatography (1:2 AcOEt-hexane) of the residue on silica gel (50 g) gave **9** (111 mg, 85%) as an amorphous mass: $[\alpha]_D^{+55.9^\circ}$ (*c* 1.2, CH_2Cl_2); 1H NMR ($CDCl_3$) δ 1.88 (s, 3H, $MeCOCH_2CH_2$), 2.27 (s, 3H, MeS), 2.41-2.58 (m, 4H, $MeCOCH_2CH_2$), 3.62 (s, 1H, H-5), 4.01 (near d, 1H, $J_{gem} = 12.5$ Hz, H-6), 4.33 (d, 1H, H-6'), 4.41 (d, 1H, $J_{3,4} = 3.5$ Hz, H-4), 4.54 (d, 1H, $J_{1,2} = 9.9$ Hz, H-1), 5.20 (dd, 1H, $J_{2,3} = 9.9$ Hz, H-3), 5.51 (s, 1H, $PhCH$), 5.73 (t, 1H, H-2), and 7.25-8.02 (m, 10H, 2Ph).

Anal. Calcd for $C_{26}H_{28}O_8S$ (500.6): C, 62.39; H, 5.64. Found: C, 62.16; H, 5.55.

2-(Trimethylsilyl)ethyl *O* - [2,4,6-Tri-*O* - benzoyl-3-*O* - (methoxycarbonyl)methyl- β -D-galactopyranosyl]-(1 \rightarrow 4)-*O* - [(2,3,4-tri-*O* - benzyl- α -L-fucopyranosyl) - (1 \rightarrow 3)]-*O* - (2-acetamido-6-*O* - benzyl-2-deoxy- β -D-glucopyranosyl)-(1 \rightarrow 3)-2,4,6-tri-*O*-benzyl- β -D-galactopyranoside (11). To a solution of 2-(trimethylsilyl)ethyl *O*-(2,3,4-tri-*O*-benzyl- α -L-fucopyranosyl)-(1 \rightarrow 3)-*O*-(2-acetamido-6-*O*-benzyl-2-deoxy- β -D-glucopyranosyl)-(1 \rightarrow 3)-2,4,6-tri-*O*-benzyl- β -D-galactopyranoside (**10**; 118 mg, 94 μ mol) and **6** (100 mg, 0.17 mmol) in CH_2Cl_2 (0.5 mL) were added molecular sieves 4 \AA (MS-4 \AA ; 218 mg), and the mixture was stirred for 8 h at room temperature. Dimethyl(methylthio)sulfonium triflate (DMTST; 266 mg) and MS-4 \AA (266 mg) were added to the stirred mixture at 7 $^\circ$ C, and the stirring was continued for 12 h at 7 $^\circ$ C. The precipitate was filtered off and washed with CH_2Cl_2 . The filtrate and washings

were combined, and the solution was washed with M Na₂CO₃ and water, dried (Na₂SO₄) and concentrated. Column chromatography (1:2 AcOEt-hexane) of the residue on silica gel (50 g) gave **11** (150 mg, 89%) as an amorphous mass: [α]_D -17.2° (*c* 1.2, CHCl₃); ¹H NMR (CDCl₃) δ 0.95 (m, 2H, Me₃SiCH₂CH₂), 1.23 (d, 3H, J_{5,6} = 6.6 Hz, H-6d), 1.65 (s, 3H, AcN), 3.56 (s, 3H, MeO), 5.30 (d, 1H, J_{1,2} = 3.5 Hz, H-1d), 5.44 (dd, 1H, J_{1,2} = 8.6 Hz, J_{2,3} = 9.5 Hz, H-2c), 5.76 (d, 1H, NH), 5.81 (bd, 1H, J_{3,4} = 3.5 Hz, H-4c), and 7.11-8.14 (m, 50H, 10Ph).

Anal. Calcd for C₁₀₄H₁₁₅NO₂₅Si (1807.1): C, 69.12; H, 6.41; N, 0.78. Found: C, 68.83; H, 6.31; N, 0.61.

2-(Trimethylsilyl)ethyl O-[2,4,6-Tri-O-benzoyl-3-O-(methoxycarbonyl)methyl- β -D-galactopyranosyl]-(1 \rightarrow 4)-O-[(2,3,4-tri-O-acetyl- α -L-fucopyranosyl)-(1 \rightarrow 3)]-O-(2-acetamido-6-O-acetyl-2-deoxy- β -D-glucopyranosyl)-(1 \rightarrow 3)-2,4,6-tri-O-acetyl- β -D-galactopyranoside (12**).** A solution of **11** (94 mg, 52 μ mol) in MeOH (15 mL) and AcOH (2.6 mL) was hydrogenolyzed in the presence of 10% Pd-C (113 mg) for 22 h at 45 °C, then filtered and concentrated. The residue was acetylated with Ac₂O (1.5 mL)-pyridine (3 mL) for 48 h at 40 °C. The product was purified by chromatography on a column of silica gel (50 g) with 2:1 AcOEt-hexane afforded **12** (47 mg, 62%) as an amorphous mass: [α]_D -26.2° (*c* 0.9, CHCl₃); ¹H NMR (CDCl₃) δ 0.92 (m, 2H, Me₃SiCH₂CH₂), 1.30 (d, 3H, J_{5,6} = 6.4 Hz, H-6d), 1.89-2.17 (7s, 24H, 7AcO and AcN), 3.50 (s, 3H, MeO), 3.59 (dd, 1H, J_{2,3} = 10.1 Hz, J_{3,4} = 3.9 Hz, H-3a), 5.24 (d, 1H, J_{1,2} = 3.5 Hz, H-1d), 5.42 (d, 1H, H-4a), 5.45 (t, 1H, J_{1,2} = J_{2,3} = 8.6 Hz, H-2c), 5.55 (d, 1H, NH), 5.91 (bd, 1H, J_{3,4} = 3.3 Hz, H-4c), and 7.46-8.13 (m, 15H, 3Ph).

Anal. Calcd for C₆₉H₈₇NO₃₂Si (1470.5): C, 56.36; H, 5.96; N, 0.95. Found: C, 56.27; H, 5.80; N, 0.74.

O-[2,4,6-Tri-O-benzoyl-3-O-(methoxycarbonyl)methyl- β -D-galactopyranosyl]-(1 \rightarrow 4)-O-[(2,3,4-tri-O-acetyl- α -L-fucopyranosyl)-(1 \rightarrow 3)]-O-(2-acetamido-6-O-acetyl-2-deoxy- β -D-glucopyranosyl)-(1 \rightarrow 3)-2,4,6-tri-O-acetyl-D-galactopyranose (13**).** Selective removal of the 2-(trimethylsilyl)ethyl group in **12** (121 mg, 82 μ mol) with trifluoroacetic acid (1 mL) in

CH₂Cl₂ (1.4 mL) as described for **4**, gave compound **13** (105 mg, 93%) as an amorphous mass: IR (film) 3500 (OH), 3350 (NH), 1720 and 1250 (ester), 1680 and 1530 (amide), and 710 cm⁻¹ (Ph).

Anal. Calcd for C₆₄H₇₅NO₃₂ (1370.3): C, 56.10; H, 5.52; N, 1.02. Found: C, 55.81; H, 5.41; N, 0.77.

O-[2,4,6-Tri-*O*-benzoyl-3-*O*-(methoxycarbonyl)methyl-β-D-galactopyranosyl]-(1→4)-*O*-[(2,3,4-tri-*O*-acetyl-α-L-fucopyranosyl)-(1→3)]-*O*-(2-acetamido-6-*O*-acetyl-2-deoxy-β-D-glucopyranosyl)-(1→3)-2,4,6-tri-*O*-acetyl-α-D-galactopyranosyl trichloroacetimidate (**14**). To a solution of **13** (105 mg, 77 μmol) in CH₂Cl₂ (1.3 mL) and trichloroacetonitrile (0.23 mL) was added DBU (12 mg) at 0 °C. A similar processing, as described for **5**, gave compound **14** (115 mg, quantitative) as an amorphous mass: [α]_D +3.6° (c 2.2, CHCl₃); ¹H NMR (CDCl₃) δ 1.30 (d, 3H, J_{5,6} = 6.6 Hz, H-6d), 1.88-2.17 (8s, 24H, 7AcO and AcN), 3.49 (s, 3H, MeO), 5.44 (m, 1H, H-2c), 5.45 (d, 1H, J_{3,4} = 3.8 Hz, H-4a), 5.64 (d, 1H, NH), 5.92 (bd, 1H, J_{3,4} = 3.3 Hz, H-4c), 6.50 (d, 1H, J_{1,2} = 3.7 Hz, H-1a), 7.46-8.12 (m, 15H, 3Ph), and 8.64 (s, 1H, C=NH).

Anal. Calcd for C₆₆H₇₅N₂O₃₂Cl₃ (1514.7): C, 52.34; H, 4.99; N, 1.85. Found: C, 52.16; H, 4.94; N, 1.58.

O-[2,4,6-Tri-*O*-benzoyl-3-*O*-(methoxycarbonyl)methyl-β-D-galactopyranosyl]-(1→4)-*O*-[(2,3,4-tri-*O*-acetyl-α-L-fucopyranosyl)-(1→3)]-*O*-(2-acetamido-6-*O*-acetyl-2-deoxy-β-D-glucopyranosyl)-(1→3)-*O*-(2,4,6-tri-*O*-acetyl-β-D-galactopyranosyl)-(1→1)-(2*S*,3*R*,4*E*)-2-azido-3-*O*-benzoyl-4-octadecene-1,3-diol (**16**). To a solution of **14** (117 mg, 77 μmol) and (2*S*,3*R*,4*E*)-2-azido-3-*O*-benzoyl-4-octadecene-1,3-diol^{16,17} (**15**; 66 mg, 0.15 mmol) in CH₂Cl₂ (2.6 mL) was added MS-4Å (type AW-300; 2.7 g), and the mixture was stirred for 3 h at room temperature, then cooled to 0 °C. Boron trifluoride etherate (57 μL) was added, and the mixture was stirred for 2 h at 0 °C and then filtered. The insoluble material was washed with CH₂Cl₂, and the combined filtrate and washings was washed with M Na₂CO₃ and water, dried (Na₂SO₄) and concentrated. Column chromatography (2:1 AcOEt-hexane) of the residue on silica gel (80 g) gave **16** (52

mg, 38%) as an amorphous mass: $[\alpha]_D -20.8^\circ$ (c 1.0, CHCl_3); IR (film) 3350 (NH), 3150-2800 (Me and methylene), 2100 (N_3), 1740 and 1230 (ester), 1680 and 1550 (amide), and 710 cm^{-1} (Ph); ^1H NMR (CDCl_3) δ 0.88 (t, 3H, MeCH_2), 1.24 (s, 22H, 11 CH_2), 1.30 (d, 3H, $J_{5,6} = 6.6\text{ Hz}$, H-6d), 1.88-2.16 (8s, 24H, 7AcO and AcN), 3.50 (s, 3H, MeO), 5.24 (d, 1H, $J_{1,2} = 3.1\text{ Hz}$, H-1d), 5.42 (m, 1H, H-4a), 5.49 (m, 1H, H-2c), 5.54 (d, 1H, NH), 5.89 (m, 1H, H-4c), 5.90 (m, 1H, H-5 of sphingosine), and 7.41-8.13 (m, 20H, 4Ph).

Anal. Calcd for $\text{C}_{89}\text{H}_{112}\text{N}_4\text{O}_{34}$ (1781.9): C, 59.99; H, 6.34; N, 3.14. Found: C, 59.96; H, 6.31; N, 2.88.

***O*-[2, 4, 6-Tri-*O*-benzoyl-3-*O*-(methoxycarbonyl)methyl- β -D-galactopyranosyl]-(1 \rightarrow 4)-*O*-[(2,3,4-tri-*O*-acetyl- α -L-fucopyranosyl)-(1 \rightarrow 3)]-*O*-(2-acetamido-6-*O*-acetyl-2-deoxy- β -D-glucopyranosyl)-(1 \rightarrow 3)-*O*-(2,4,6-tri-*O*-acetyl- β -D-galactopyranosyl)-(1 \rightarrow 1)-(2*S*,3*R*,4*E*)-3-*O*-benzoyl-2-octadecanamido-4-octadecene-1,3-diol (17).** Hydrogen sulfide was bubbled through a stirred solution of **16** (52 mg, 29 μmol) in aqueous 83% pyridine (6 mL) for 50 h at 0 $^\circ\text{C}$. The mixture was concentrated, and the residue was stirred with octadecanoic acid (35 mg, 0.12 mmol) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (35 mg) in CH_2Cl_2 (2.9 mL) for 13 h at room temperature. CH_2Cl_2 (50 mL) was added, and the mixture was washed with water, dried (Na_2SO_4) and concentrated. Column chromatography (2:1 AcOEt-hexane) of the residue on silica gel (40 g) gave **17** (36 mg, 61%) as an amorphous mass: $[\alpha]_D -7.4^\circ$ (c 1.2, CHCl_3); ^1H NMR (CDCl_3) δ 0.88 (t, 6H, 2 MeCH_2), 1.26 (s, 52H, 26 CH_2), 1.28 (m, 3H, H-6d), 1.89-2.16 (8s, 24H, 7AcO and AcN), 3.50 (s, 3H, MeO), 5.20 (d, 1H, $J_{1,2} = 3.5\text{ Hz}$, H-1d), 5.80 (m, 1H, H-5 of sphingosine), and 7.40-8.12 (m, 20H, 4Ph).

Anal. Calcd for $\text{C}_{107}\text{H}_{148}\text{N}_2\text{O}_{35}$ (2022.3): C, 63.55; H, 7.38; N, 1.39. Found: C, 63.45; H, 7.32; N, 1.31.

***O*-(3-*O*-Carboxymethyl- β -D-galactopyranosyl)-(1 \rightarrow 4)-*O*-[α -L-fucopyranosyl-(1 \rightarrow 3)]-*O*-(2-acetamido-2-deoxy- β -D-glucopyranosyl)-(1 \rightarrow 3)-*O*-(β -D-galactopyranosyl)-(1 \rightarrow 1)-(2*S*,3*R*,4*E*)-2-octadecanamido-4-**

octadecene-1,3-diol (18). To a solution of **17** (36 mg, 18 μ mol) in MeOH (5 mL) was added sodium methoxide (60 mg), and the mixture was stirred for 17 h at 40 °C, and water (1 mL) was added. The solution was stirred for 24 h at 40 °C, then treated with Amberlite IR-120 (H⁺) resin and filtered. The resin was washed with 1:1 CHCl₃-MeOH, and the combined filtrate and washings were concentrated. Column chromatography (1:1 CHCl₃-MeOH) of the residue on Sephadex LH-20 (70 g) gave **18** (22 mg, quantitative) as an amorphous mass: $[\alpha]_D -19.2^\circ$ (*c* 0.7, 1:1 CHCl₃-MeOH); ¹H NMR (1:1 CDCl₃-CD₃OD) δ 0.89 (t, 6H, 2*Me*CH₂), 1.21 (d, 3H, J_{5,6} = 6.1 Hz, H-6d), 1.27 (s, 52H, 26CH₂), 2.00 (s, 3H, AcN), 2.17 (t, 2H, COCH₂CH₂), 4.48 (d, 1H, J_{1,2} = 7.9 Hz, H-1 of Gal), 5.09 (d, 1H, J_{1,2} = 3.5 Hz, H-1d), 5.45 (dd, 1H, J_{3,4} = 7.3 Hz, J_{4,5} = 15.4 Hz, H-4 of sphingosine), and 5.70 (dt, 1H, J_{5,6} = J_{5,6'} = 7.1 Hz, H-5 of sphingosine).

Anal. Calcd for C₆₄H₁₁₆N₂O₂₄ (1297.6): C, 59.24; H, 9.01; N, 2.16. Found: C, 59.18; H, 8.77; N, 1.99.

2-(Trimethylsilyl)ethyl O-(2-O-Benzoyl-4,6-O-benzylidene-3-O-levulinoyl- β -D-galactopyranosyl)-(1 \rightarrow 4)-O-[(2,3,4-tri-O-benzyl- α -L-fucopyranosyl)-(1 \rightarrow 3)]-O-(2-acetamido-6-O-benzyl-2-deoxy- β -D-glucopyranosyl)-(1 \rightarrow 3)-2,4,6-tri-O-benzyl- β -D-galactopyranoside (19). Glycosylation of **10** (150 mg, 0.12 mmol) with **9** (110 mg, 0.22 mmol) in CH₂Cl₂ (1 mL) in the presence of DMTST and MS-4 \AA (650 mg, 52% DMTST by weight) for 84 h at 7 °C, as described for **11**, gave compound **19** (94 mg, 46%) as an amorphous mass: $[\alpha]_D +0.2^\circ$ (*c* 1.9, CHCl₃); ¹H NMR (CDCl₃) δ 0.92 (Me₃SiCH₂CH₂), 1.26 (d, 3H, J_{5,6} = 7.0 Hz, H-6d), 1.95 (s, 3H, AcN), 2.03 (s, 3H, MeCOCH₂CH₂), 2.48-2.76 (m, 4H, MeCOCH₂CH₂), 4.96 (dd, 1H, J_{2,3} = 9.9 Hz, J_{3,4} = 3.7 Hz, H-3c), 4.98 (d, 1H, J_{1,2} = 3.3 Hz, H-1d), 5.56 (s, 1H, PhCH), 5.59 (dd, 1H, J_{1,2} = 8.4 Hz, H-2c), and 7.15-8.08 (m, 45H, 9Ph).

Anal. Calcd for C₉₉H₁₁₃NO₂₃Si (1713.1): C, 69.41; H, 6.65; N, 0.82. Found: C, 69.21; H, 6.48; N, 0.55.

2-(Trimethylsilyl)ethyl O-(2-O-Benzoyl-4,6-O-benzylidene-3-O-levulinoyl- β -D-galactopyranosyl)-(1 \rightarrow 4)-O-[(2,3,4-tri-O-acetyl- α

-L-fucopyranosyl)-(1 → 3)]-O-(2-acetamido-6-O-acetyl-2-deoxy-β-D-glucopyranosyl)-(1 → 3)-2,4,6-tri-O-acetyl-β-D-galactopyranoside (20).

A solution of **19** (100 mg, 58 μmol) in EtOH (15 mL) and AcOH (2.6 mL) was hydrogenolyzed in the presence of 10% Pd-C (120 mg) for 48 h at 40 °C, and subsequent acetylation with Ac₂O (2 mL) in pyridine (4 mL) as described for **12**, gave compound **20** (65 mg, 81%) as an amorphous mass: [α]_D -24.3° (*c* 1.2, CHCl₃); ¹H NMR (CDCl₃) δ 0.73 (d, 3H, J_{5,6} = 6.4 Hz, H-6d), 0.91 (m, 2H, Me₃SiCH₂CH₂), 1.97-2.12 (9s, 27H, 7AcO, AcN and MeCOCH₂CH₂), 2.39-2.64 (m, 4H, MeCOCH₂CH₂), 3.50 and 3.93 (m, 2H, Me₃SiCH₂CH₂), 3.67 (dd, 1H, J_{2,3} = 10.2 Hz, J_{3,4} = 3.6 Hz, H-3a), 4.39 and 4.74 (2d, 2H, J_{1,2} = 8.1 Hz, J_{1,2} = 8.3 Hz, H-1a and H-1c), 5.57 (s, 1H, PhCH), and 7.28-8.05 (m, 10H, 2Ph).

Anal. Calcd for C₆₄H₈₅NO₃₀Si (1376.5): C, 55.85; H, 6.22; N, 1.02. Found: C, 55.76; H, 6.14; N, 0.98.

2-(Trimethylsilyl)ethyl O-(4,6-Di-O-acetyl-2-O-benzoyl-3-O-levulinoyl-β-D-galactopyranosyl)-(1 → 4)-O-[(2,3,4-tri-O-acetyl-α-L-fucopyranosyl)-(1 → 3)]-O-(2-acetamido-6-O-acetyl-2-deoxy-β-D-glucopyranosyl)-(1 → 3)-2,4,6-tri-O-acetyl-β-D-galactopyranoside (21).

Hydrogenolysis of **20** (140 mg, 0.10 mmol) in EtOH (16 mL) and AcOH (4 mL) in the presence of PdCl₂ (150 mg) for 24 h at 40 °C, and subsequent acetylation with Ac₂O (1.5 mL)-pyridine (3 mL) as described for **12**, gave compound **21** (87 mg, 62%) as an amorphous mass: [α]_D -47.5° (*c* 1.1, CHCl₃); ¹H NMR (CDCl₃) δ 0.92 (m, 2H, Me₃SiCH₂CH₂), 1.31 (d, 3H, J_{5,6} = 6.6 Hz, H-6d), 1.92-2.22 (10s, 33H, 9AcO, AcN and MeCOCH₂CH₂), 2.27-2.67 (m, 4H, MeCOCH₂CH₂), 3.50 (m, 1H, Me₃SiCH₂CH), 3.63 (dd, 1H, J_{2,3} = 10.0 Hz, J_{3,4} = 3.6 Hz, H-3a), 4.30 and 4.73 (2d, 2H, J_{1,2} = 7.9 Hz, J_{1,2} = 8.1 Hz, H-1a and H-1c), and 7.29-8.02 (m, 5H, Ph).

Anal. Calcd for C₆₁H₈₅NO₃₂Si (1372.4): C, 53.39; H, 6.24; N, 1.02. Found: C, 53.36; H, 6.01; N, 0.97.

O-(4,6-Di-O-acetyl-2-O-benzoyl-3-O-levulinoyl-β-D-galactopyranosyl)-(1 → 4)-O-[(2,3,4-tri-O-acetyl-α-L-fucopyranosyl)-(1 → 3)]-O-(2-acetamido-6-O-acetyl-2-deoxy-β-D-glucopyranosyl)-(1 → 3)-

2,4,6-tri-*O*-acetyl-*D*-galactopyranose (22). Selective removal of the 2-(trimethylsilyl)ethyl group in **21** (209 mg, 0.15 mmol) with trifluoroacetic acid (1.7 mL) in CH₂Cl₂ (2.4 mL) as described for **4**, gave compound **22** (173 mg, 89%) as an amorphous mass: IR (film) 3500 (OH), 3350 (NH), 1750 and 1240 (ester), 1680 and 1530 (amide), and 710 cm⁻¹ (Ph).

Anal. Calcd for C₅₆H₇₃NO₃₂ (1272.2): C, 52.87; H, 5.78; N, 1.10. Found: C, 52.59; H, 5.71; N, 0.88.

***O*-(4,6-Di-*O*-acetyl-2-*O*-benzoyl-3-*O*-levulinoyl- β -*D*-galactopyranosyl)-(1 \rightarrow 4)-*O*-[(2,3,4-tri-*O*-acetyl- α -*L*-fucopyranosyl)-(1 \rightarrow 3)]-*O*-(2-acetamido-6-*O*-acetyl-2-deoxy- β -*D*-glucopyranosyl)-(1 \rightarrow 3)-2,4,6-tri-*O*-acetyl- α -*D*-galactopyranosyl trichloroacetimidate (23).** To a stirred solution of **22** (169 mg, 0.13 mmol) in CH₂Cl₂ (2.1 mL), cooled to 0 °C, were added trichloroacetonitrile (0.4 mL) and DBU (20 mg), and the mixture was stirred for 1 h at 0 °C. A similar processing, as described for **5**, gave compound **23** (187 mg, quantitative) as an amorphous mass: [α]_D -7.4° (*c* 1.3, CHCl₃); ¹H NMR (CDCl₃) δ 1.30 (d, 3H, J_{5,6} = 6.6 Hz, H-6d), 1.98-2.22 (10s, 33H, 9AcO, AcN and MeCOCH₂CH₂), 2.27-2.66 (m, 4H, MeCOCH₂CH₂), 6.48 (d, 1H, J_{1,2} = 3.9 Hz, H-1a), 7.46-8.02 (m, 5H, Ph), and 8.63 (s, 1H, C=NH).

Anal. Calcd for C₅₈H₇₃N₂O₃₂Cl₃ (1416.6): C, 49.18; H, 5.19; N, 1.98. Found: C, 49.07; H, 5.18; N, 1.81.

2-(Tetradecyl)hexadecyl *O*-(4,6-Di-*O*-acetyl-2-*O*-benzoyl-3-*O*-levulinoyl- β -*D*-galactopyranosyl)-(1 \rightarrow 4)-*O*-[(2,3,4-tri-*O*-acetyl- α -*L*-fucopyranosyl)-(1 \rightarrow 3)]-*O*-(2-acetamido-6-*O*-acetyl-2-deoxy- β -*D*-glucopyranosyl)-(1 \rightarrow 3)-2,4,6-tri-*O*-acetyl- β -*D*-galactopyranoside (25). Coupling of **23** (187 mg, 0.13 mmol) and 2-(tetradecyl)hexadecan-1-ol²⁰ (**24**; 120 mg, 0.27 mmol) in CH₂Cl₂ (2.6 mL), as described for **16**, gave compound **25** (83 mg, 37%) as an amorphous mass: [α]_D -34.7° (*c* 1.5, CHCl₃); IR (film) 3350 (NH), 3150-2800 (Me and methylene), 1720 and 1250 (ester), 1650 and 1560 (amide), and 700 cm⁻¹ (Ph); ¹H NMR (CDCl₃) δ 0.88 (t, 6H, 2MeCH₂), 1.26 (s, 52H, 26CH₂), 1.31 (d, 3H, J_{5,6} = 6.6 Hz, H-6d), 1.92-2.22 (10s, 33H, 9AcO, AcN and

MeCOCH₂CH₂), 2.27-2.67 (m, 4H, *MeCOCH₂CH₂*), 3.09 (m, 1H, H-1 of lipophilic part), 3.63 (dd, 1H, $J_{2,3} = 10.1$ Hz, $J_{3,4} = 3.5$ Hz, H-3a), 4.73 (d, 1H, $J_{1,2} = 8.1$ Hz, H-1 of Gal), and 7.45-8.02 (m, 5H, Ph).

Anal. Calcd for C₈₆H₁₃₃NO₃₂ (1693.0): C, 61.01; H, 7.92; N, 0.83. Found: C, 60.95; H, 7.92; N, 0.64.

2-(Tetradecyl)hexadecyl O-(4,6-Di-O-acetyl-2-O-benzoyl-β-D-galactopyranosyl)-(1 → 4)-O-[(2,3,4-tri-O-acetyl-α-L-fucopyranosyl)-(1 → 3)]-O-(2-acetamido-6-O-acetyl-2-deoxy-β-D-glucopyranosyl)-(1 → 3)-2,4,6-tri-O-acetyl-β-D-galactopyranoside (26). To a solution of **25** (83 mg, 49 μmol) in EtOH (1.6 mL) was added hydrazine acetate (5.4 mg, 59 μmol) and the mixture was stirred for 2 h at room temperature then concentrated. Column chromatography (3:2 AcOEt-hexane) of the residue on silica gel (50 g) gave **26** (68 mg, 87%) as an amorphous mass: $[\alpha]_D -42.0^\circ$ (*c* 1.3, CHCl₃); ¹H NMR (CDCl₃) δ 0.88 (t, 6H, 2*MeCH₂*), 1.25 (s, 52H, 26CH₂), 1.30 (d, 3H, $J_{5,6} = 5.9$ Hz, H-6d), 1.91-2.23 (10s, 30H, 9AcO and AcN), 3.65 (dd, 1H, $J_{2,3} = 10.1$ Hz, $J_{3,4} = 3.5$ Hz, H-3a), 4.25 and 4.65 (2d, 2H, $J_{1,2} = 7.9$ Hz, $J_{1,2} = 8.2$ Hz, H-1a and H-1c), and 7.45-8.06 (m, 5H, Ph).

Anal. Calcd for C₈₁H₁₂₇NO₃₀ (1594.9): C, 61.00; H, 8.03; N, 0.88. Found: C, 60.83; H, 7.93; N, 0.78.

2-(Tetradecyl)hexadecyl O-(3-O-Sulfo-β-D-galactopyranosyl)-(1 → 4)-O-[α-L-fucopyranosyl-(1 → 3)]-O-(2-acetamido-2-deoxy-β-D-glucopyranosyl)-(1 → 3)-β-D-galactopyranoside sodium salt (28). To a solution of **26** (29 mg, 18 μmol) in *N,N*-dimethylformamide (0.3 mL) was added sulfur trioxide-pyridine complex (30 mg, 0.19 mmol) and the mixture was stirred for 4 h at room temperature; the course of the reaction was monitored by TLC. MeOH (1 mL) was added, and the mixture was concentrated at 25 °C. Column chromatography (5:1 CH₂Cl₂-MeOH) of the residue on silica gel (50 g) gave the pyridine salt (**27**; 30 mg, quantitative) as an amorphous mass, and subsequently to a solution of **27** (30 mg, 17 μmol) in MeOH (2.5 mL) and tetrahydrofuran (2.5 mL) was added sodium methoxide (60 mg) and the mixture was stirred for 92 h at room temperature then concentrated at

25 °C. Column chromatography (5:4:0.7 CHCl₃-MeOH-water) of the residue on Sephadex LH-20 (80 g) gave **28** (19 mg, quantitative) as an amorphous mass: ¹H NMR (C₅D₅N) δ 0.88 (t, 6H, 2*Me*CH₂), 1.15 (d, 3H, J_{5,6} = 6.6 Hz, H-6d), 1.28 (s, 52H, 26CH₂), 1.96 (s, 3H, AcN), and 5.09 (bd, 1H, H-1d). The mass spectrum of **28** (negative ion mode) showed the base peak at *m/z* 1190.7 (M-H)⁻.

2-(Tetradecyl)hexadecyl O-[4,6-Di-O-acetyl-2-O-benzoyl-3-O-(*o*-xylylenedioxyphosphinyl)-β-D-galactopyranosyl]-(1 → 4)-O-[(2,3,4-tri-O-acetyl-α-L-fucopyranosyl)-(1 → 3)]-O-(2-acetamido-6-O-acetyl-2-deoxy-β-D-glucopyranosyl)-(1 → 3)-2,4,6-tri-O-acetyl-β-D-galactopyranoside (29). A suspension of **26** (32 mg, 20 μmol) and 1*H*-tetrazole (4 mg) in CH₂Cl₂ (0.3 mL) was added *o*-xylylene *N,N*-diethylphosphoramidite (20 mg, 84 μmol), and the mixture was stirred for 13 h at room temperature; the course of the reaction was monitored by TLC. The resulting solution was directly applied for preparative thin layer chromatography (20 x 20 cm, 2 mm, Merck Co.; 15:1 CH₂Cl₂-MeOH) gave **29** (24 mg, 69%) as an amorphous mass: [α]_D -7.5° (*c* 0.8, CHCl₃); ¹H NMR (CDCl₃) δ 0.88 (t, 6H, 2*Me*CH₂), 1.26 (s, 52H, 26CH₂), 1.34 (d, 3H, J_{5,6} = 6.6 Hz, H-6d), 1.92-2.24 (10s, 30H, 9AcO and AcN), 3.63 (dd, 1H, J_{3,4} = 3.3 Hz, H-3a), 4.09, 4.47, 5.47, and 5.62 [4dd, 4H, J_{gem} = 10.3 Hz, J_{P,H} = 13.6 Hz, P(OCH₂)₂], 4.24 and 4.69 (2d, 2H, J_{1,2} = 8.1 Hz, J_{1,2} = 8.1 Hz, H-1a and H-1c), 5.62 (bd, 1H, J_{3,4} = 3.5 Hz, H-4c), and 7.00-8.07 (m, 9H, aromatic protons).

Anal. Calcd for C₈₉H₁₃₄NO₃₂P (1761.0): C, 60.70; H, 7.67; N, 0.86. Found: C, 60.56; H, 7.53; N, 0.65.

2-(Tetradecyl)hexadecyl O-[4,6-Di-O-acetyl-2-O-benzoyl-3-O-(*o*-xylylenedioxyphosphoryl)-β-D-galactopyranosyl]-(1 → 4)-O-[(2,3,4-tri-O-acetyl-α-L-fucopyranosyl)-(1 → 3)]-O-(2-acetamido-6-O-acetyl-2-deoxy-β-D-glucopyranosyl)-(1 → 3)-2,4,6-tri-O-acetyl-β-D-galactopyranoside (30). To a solution of **29** (24 mg, 14 μmol) in CH₂Cl₂ (0.25 mL), cooled to 0 °C, was added dropwise, with stirring, a solution of 3-chloroperoxybenzoic acid (50-60% by weight; 5 mg, 14 μmol) in CH₂Cl₂ (0.1 mL), and the stirring was continued for 1 h at room temperature. CH₂Cl₂ (50 mL) was added, and the solution

was washed with M Na₂CO₃ and water, dried (Na₂SO₄) and concentrated. Column chromatography (50:1 CH₂Cl₂-MeOH) of the residue on silica gel (40 g) gave **30** (20 mg, 83%) as an amorphous mass: $[\alpha]_D -13.5^\circ$ (*c* 0.7, CHCl₃); ¹H NMR (CDCl₃) δ 0.88 (t, 6H, 2*Me*CH₂), 1.26 (s, 52H, 26CH₂), 1.92-2.22 (10s, 30H, 9AcO and AcN), 3.63 (dd, 1H, J_{3,4} = 3.5 Hz, H-3a), 4.24 (d, 1H, J_{1,2} = 7.9 Hz, H-1 of Gal), 4.63-4.77 and 4.94-5.05 [m, 4H, P(OCH₂)₂], 5.39 (m, 1H, H-2c), 5.68 (bd, 1H, J_{3,4} = 3.5 Hz, H-4c), and 6.96-8.14 (m, 9H, aromatic protons).

Anal. Calcd for C₈₉H₁₃₄NO₃₃P (1777.0): C, 60.16; H, 7.60; N, 0.79. Found: C, 60.11; H, 7.41; N, 0.57.

2-(Tetradecyl)hexadecyl O-(3-O-Phosphono- β -D-galactopyranosyl)-(1 \rightarrow 4)-O-[α -L-fucopyranosyl-(1 \rightarrow 3)]-O-(2-acetamido-2-deoxy- β -D-glucopyranosyl)-(1 \rightarrow 3)- β -D-galactopyranoside sodium salt (31**).** A solution of **30** (20 mg, 11 μ mol) in MeOH (1 mL) was stirred for 8 h at room temperature in the presence of 10% Pd-C (17 mg) under hydrogen, then filtered and concentrated at 25 $^\circ$ C. To a solution of the residue in MeOH (3 mL) and tetrahydrofuran (3 mL) was added sodium methoxide (60 mg), and the mixture was stirred for 6 days at room temperature then concentrated at 25 $^\circ$ C. Column chromatography (5:4:0.7 CHCl₃-MeOH-water) of the residue on Sephadex LH-20 (80 g) gave **31** (12 mg, quantitative) as an amorphous mass: ¹H NMR (C₅D₅N) δ 0.88 (t, 6H, 2*Me*CH₂), 1.13 (d, 3H, J_{5,6} = 6.6 Hz, H-6d), 1.30 (s, 52H, 26CH₂), 2.00 (s, 3H, AcN), and 5.13 (bd, 1H, H-1d). The mass spectrum of **31** (negative ion mode) showed the base peak at *m/z* 1234.6 (M-H)⁻, 1212.7 (M-Na)⁻, and 1190.7 (M-2Na+H)⁻.

ACKNOWLEDGMENT

This work was supported in part by Grant-in-Aid (No. 07273226 and No. 05274102) for Scientific Research on Priority Areas from the Ministry of Education, Science and Culture of Japan.

REFERENCES

1. H. Pauvala, *J. Biol. Chem.*, **251**, 7517 (1976).
2. K. Fukushima, M. Hirota, P. I. Terasaki, A. Wakisaka, H. Togashi, D. Chia, N. Suyama, Y. Fukushi, E. Nudelman, and S. Hakomori, *Cancer Res.*, **44**, 5279 (1984).
3. M. P. Bevilacqua, S. Stengelin, M. A. Gimbrone, Jr. and B. Seed, *Science*, **243**, 1160 (1989).
4. G. I. Johnston, R. G. Cook and R. P. McEver, *Cell*, **56**, 1033 (1989).
5. L. A. Lasky, M. S. Singer, T. A. Yednock, D. Dowbenko, C. Fennie, H. Rodriguez, T. Nguyen, S. Stachel and S. D. Rosen, *Cell*, **56**, 1045 (1989).
6. T. F. Tedder, C. M. Isaacs, E. J. Ernst, G. D. Demetri, D. A. Adler and C. M. Disteche, *J. Exp. Med.*, **170**, 123 (1989).
7. A. Hasegawa, K. Ito, H. Ishida, and M. Kiso, *J. Carbohydr. Chem.*, **14**, 353 (1995).
8. a) H. Ohmoto, K. Nakamura, T. Inoue, N. Kondo, Y. Inoue, K. Yoshino, H. Kondo, H. Ishida, M. Kiso, and A. Hasegawa, *J. Med. Chem.*, in press; b) Y. Wada, T. Saito, N. Matsuda, H. Ohmoto, K. Yoshino, M. Ohashi, H. Kondo, H. Ishida, M. Kiso, and A. Hasegawa, *ibid.*, submitted.
9. A. Hasegawa, T. Ando, A. Kameyama, and M. Kiso, *J. Carbohydr. Chem.*, **11**, 645 (1992).
10. K. Jansson, S. Ahlfors, T. Frejd, J. Kihlberg, G. Magnusson, J. Dahmen, G. Noori, and K. Stenvall, *J. Org. Chem.*, **53**, 5629 (1988).
11. K. Leontein, M. Nilsson, and T. Norberg, *Carbohydr. Res.*, **144**, 231 (1985).
12. P. Fügedi and P. J. Garegg, *Carbohydr. Res.*, **149**, c9 (1986).
13. M. Ravenscroft, R. M. G. Robert and J. G. Tillett, *J. Chem. Soc., Perkin Trans. 2*, 1569 (1982).
14. R. R. Schmidt, and G. Grundler, *Synthesis*, 885 (1981).
15. T. Murase, A. Kameyama, K. P. R. Kartha, H. Ishida, M. Kiso, and A. Hasegawa, *J. Carbohydr. Chem.*, **8**, 265 (1989).
16. Y. Ito, M. Kiso, and A. Hasegawa, *J. Carbohydr. Chem.*, **8**, 285 (1989).
17. R. R. Schmidt, and P. Zimmermann, *Angew. Chem. Int. Ed. Engl.*, **25**, 725 (1986).
18. T. Adachi, Y. Yamada, I. Inoue, and M. Saneyoshi, *Synthesis*, 45 (1977).
19. T. Murase, H. Ishida, M. Kiso, and A. Hasegawa, *Carbohydr. Res.*, **188**, 71 (1989).
20. S. Ladisch, A. Hasegawa, R. Li, and M. Kiso, *Biochem. Biophys. Res. Commun.*, **203**, 1102 (1994).
21. Y. Watanabe, Y. Komoda, K. Ebisuya, and S. Ozaki, *Tetrahedron Lett.*, **31**, 255 (1990).
22. S. Ozaki, Y. Kondo, N. Shiotani, T. Ogasawara, and Y. Watanabe, *J. Chem. Soc. Perkin. Trans. 1*, 729 (1992).